title: T-3811. Toyama/Bristol-Myers Squibb.
abstract: Toyama and Bristol-Myers Squibb (BMS) are developing the des-F(6)-quinolone T-3811 (BMS-284756) as a potential treatment for bacterial infections, including respiratory and urinary tract infections, and skin and soft tissue infections. The drug is in phase II trials in the US and Europe, and an injectable formulation began phase I trials in the US in April 2000. Phase I trials commenced in Japan in September 1999. Phase III trials were expected to begin outside Japan in 2000. T-3811 is expected to be administered as an oral or injectable once-a-day formulation. Preclinical studies suggests it has a better side-effect profile than commonly associated with other quinolones on the market. Bristol-Myers Squibb has acquired worldwide development and marketing rights, with the exception of Japan, South Korea, Taiwan and China. In December 2001, Morgan Stanley predicted that T-3811 could have peak sales potential exceeding $500 million if the positive clinical data released at this year's ICAAC continued, and that BMS was on track for filing in 3Q02.
authors.affiliation: Paratek Pharmaceuticals Inc, Boston, MA 02111, USA. rfrechette@paratekpharm.com
authors.forename: R
authors.initials: R
authors.lastname: Frechette
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D054833:Isoindoles; D015363:Quinolones / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship
chemical_list: D000890:Anti-Infective Agents; D007211:Indoles; D054833:Isoindoles; D015363:Quinolones; C118960:T 3811ME